Thu, Dec 18, 2014, 9:41 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

AxoGen, Inc. Message Board

faststocks7 19 posts  |  Last Activity: Dec 11, 2014 11:57 AM Member since: Feb 21, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Buy a few shares of this penny stock and gift them to your friends. 100 shares cost less than fifty bucks and it can become very valuable next year because BioLargo owns the biggest breakthrough in water treatment in decades that will very likely become one of the world's most valuable technologies. And they are moving quickly to commercialization in a $350 billion industry that needs them.

    Sentiment: Strong Buy

  • Millennium Healthcare (MHCC) just reported $6.3 million, a 1,200%+ increase in quarter revenues in its recent 10Q filing.

    Because Millennium’s diagnostics are preventive, FDA approved, reimbursable and cost patients little to nothing, and because they add significant income for physicians, sales are beginning to increase exponentially. Projected growth is remarkable.

    And Millennium’s gross margins are exceptionally high as the equipment and associated costs can pay for themselves in the first 30 days of installation.

    Millennium’s network of 1,300 physician offices is growing dramatically and sales and earnings are in the early part of a steep growth curve. There are over 30,000 primary care offices and most of them are going to want MHCC exclusive diagnostics.

    $6.3 million was achieved with only a small number of Millennium’s the current 1,300 physician offices.

    Millennium has the potential to sign a large number of the 30,000 plus offices.

    At 30-50 cents Millennium shares are a ground floor opportunity.

    Shares are oversold and exceptionally cheap because the company has paid millions in fees (reported in 10Q) to consultants with shares of stock that they have been selling heavily to convert to cash. This heavy selling has depressed shares prices to a very attractive entry point.

    Invest a few minutes of your time to read the 10Q for yourself and confirm an exceptional buying opportunity.

    Recommend taking advantage of current tax selling low price and putting into your portfolio now.

    MHCC 12 month target - $6.00

    Sentiment: Strong Buy

  • Millennium Healthcare (MHCC) just reported $6.3 million, a 1,200%+ increase in quarter revenues in its recent 10Q filing.

    Because Millennium’s diagnostics are preventive, FDA approved, reimbursable and cost patients little to nothing, and because they add significant income for physicians, sales are beginning to increase exponentially. Future growth is unusually large.

    And Millennium’s gross margins are exceptionally high as the equipment and associated costs can pay for themselves in the first 30 days of installation.

    Millennium’s network of 1,300 physician offices is growing dramatically and sales and earnings are in the early part of a steep growth curve. There are over 30,000 primary care offices and most of them are going to want MHCC exclusive diagnostics.

    $6.3 million was achieved with only a small number of Millennium’s the current 1,300 physician offices.

    Millennium has the potential to sign a large number of the 30,000 plus offices.

    At 30-50 cents Millennium shares are a ground floor opportunity.

    Shares are oversold and exceptionally cheap because the company has paid millions in fees (reported in 10Q) to consultants with shares of stock that they have been selling heavily to convert to cash. This heavy selling has depressed shares prices to a very attractive entry point.

    Invest a few minutes of your time to read the 10Q for yourself and confirm an exceptional buying opportunity.

    Recommend taking advantage of current tax selling low price and putting into your portfolio now.

    MHCC 12 month target - $6.00.

    Sentiment: Strong Buy

  • Millennium Healthcare (MHCC) just reported $6.3 million, a 1,200%+ increase in quarter revenues in its recent 10Q filing.

    Because Millennium’s diagnostics are preventive, FDA approved, reimbursable and cost patients little to nothing, and because they add significant income for physicians, sales are beginning to increase exponentially. Future growth is unusually large.

    And Millennium’s gross margins are exceptionally high as the equipment and associated costs can pay for themselves in the first 30 days of installation.

    Millennium’s network of 1,300 physician offices is projected to grow dramatically and sales and earnings are in the early part of a steep growth curve.

    $6.3 million was achieved with only a small number of Millennium’s the current 1,300 physician offices.

    There are over 30,000 primary care offices.

    Millennium has the potential to sign a large number of the 30,000 plus offices.

    At 30-50 cents Millennium shares are a ground floor opportunity.

    Shares are oversold and exceptionally cheap because the company has paid millions in fees (reported in 10Q) to consultants with shares of stock that they have been selling heavily to convert to cash. This heavy selling has depressed shares prices to a very attractive entry point.

    Invest a few minutes of your time to read the 10Q for yourself and confirm an exceptional buying opportunity.

    MHCC 12 month target - $6.00.

    Sentiment: Strong Buy

  • Millennium Healthcare (MHCC) just reported $6.3 million, a 1,200%+ increase in quarter revenues in its recent 10Q filing.

    Because Millennium’s diagnostics are preventive, FDA approved, reimbursable and cost patients little to nothing, and because they add significant income for physicians, sales are beginning to increase exponentially. Future growth is unusually large.

    And Millennium’s gross margins are exceptionally high as the equipment and associated costs can pay for themselves in the first 30 days of installation.

    Millennium’s network of 1,300 physician offices is projected to grow dramatically and sales and earnings are in the early part of a steep growth curve.

    $6.3 million was achieved with only a small number of Millennium’s the current 1,300 physician offices.

    There are over 30,000 primary care offices.

    Millennium has the potential to sign a large number of the 30,000 plus offices.

    At 20-40 cents Millennium shares are a ground floor opportunity.

    Shares are oversold and exceptionally cheap because the company has paid millions in fees (reported in 10Q) to consultants with shares of stock that they have been selling heavily to convert to cash. This heavy selling has depressed shares prices to a very attractive entry point.

    Invest a few minutes of your time to read the 10Q for yourself and confirm an exceptional opportunity.

    MHCC 12 month target - $6.00.

    Sentiment: Strong Buy

  • Millennium Healthcare (MHCC) just reported $6.3 million, a 1,200%+ increase in quarter revenues in its recent 10Q filing.

    Because Millennium’s diagnostics are preventive, FDA approved, reimbursable and cost patients little to nothing, and because they add significant income for physicians, sales are beginning to increase exponentially. Future growth is unusually large.

    And Millennium’s gross margins are exceptionally high as the equipment and associated costs can pay for themselves in the first 30 days of installation.

    Millennium’s network of 1,300 physician offices is projected to grow dramatically and sales and earnings are in the early part of a steep growth curve.

    $6.3 million was achieved with only a small number of Millennium’s the current 1,300 physician offices.

    There are over 30,000 primary care offices.

    Millennium has the potential to sign a large number of the 30,000 plus offices.

    At 20-40 cents Millennium shares are a ground floor opportunity.

    Shares are oversold and exceptionally cheap because the company has paid millions in fees (reported in 10Q) to consultants with shares of stock that they have been selling heavily to convert to cash. This heavy selling has depressed shares prices to a very attractive entry point.

    Invest a few minutes of your time to read the 10Q for yourself and confirm an exceptional opportunity.

    MHCC 12 month target - $6.00.

    Sentiment: Strong Buy

  • Millennium Healthcare (MHCC) just reported $6.3 million, a 1,200%+ increase in revenues in its recent 10Q filing.

    Existing and fast-growing revenues reduce risk dramatically.

    Because Millennium’s diagnostics are preventive, FDA approved, reimbursable and cost patients little to nothing, and because they add significant income for physicians, sales are beginning to increase exponentially as evidenced by the latest 10Q filing. Future growth is unusually large.

    And Millennium’s gross margins are exceptionally high as the equipment and associated costs can pay for themselves in the first 30 days of installation.

    Millennium’s network of 1,300 physician offices is projected to grow dramatically and sales and earnings are in the early part of a steep growth curve.

$6.3 million was achieved with only a small number of Millennium’s the current 1,300 physician offices.

    There are over 30,000 primary care offices.

Millennium has the potential to sign a large number of the 30,000 plus offices.

    At 20-40 cents Millennium shares are a ground floor opportunity.

    Shares are oversold and exceptionally cheap because the company has paid millions in fees (reported in 10Q) to consultants with shares of stock that they have been selling heavily to convert to cash. This heavy selling has depressed shares prices to a very attractive entry point.

    Invest a few minutes of your time to read the 10Q for yourself and confirm an exceptional opportunity.

MHCC 12 month target - $6.00.

    Sentiment: Strong Buy

  • Reply to

    BioLargo Is On the Oil Industry’s Radar Again

    by stocks4show Nov 12, 2014 8:56 AM
    faststocks7 faststocks7 Nov 23, 2014 10:26 AM Flag

    The AOS Filter will also have a big impact on fracking and refining and will create huge cost savings

    Sentiment: Strong Buy

  • Reply to

    BioLargo Is On the Oil Industry’s Radar Again

    by ajkauffman Nov 12, 2014 8:52 AM
    faststocks7 faststocks7 Nov 23, 2014 9:41 AM Flag

    Check it out . . . BioLargo's AOS Filter will also have big impact on natural gas, fracking and refining.

    Sentiment: Strong Buy

  • Millennium Healthcare (MHCC) just reported its Sep quarter revenues at $6.3 million versus $489,000, a 1,200% increase.

    Because Millennium’s diagnostics are preventive, FDA approved, reimbursable and cost patients little to nothing, and because they add significant income for physicians, sales are beginning to increase exponentially.

    Millennium’s gross margins are exceptionally high as the equipment and associated costs typically pays for themselves in the first 30 days of installation.

    Millennium’s network is growing dramatically.

    $6.3 million was achieved with only a small number of Millennium’s the current 1,300 physician offices.

    There are over 30,000 primary care offices.

    Millennium has the potential to sign a large number of the 30,000 plus offices.

    At 40 cents, Millennium shares are a ground floor opportunity.

    Shares are exceptionally cheap today because the company has paid many professional fees with shares of stock that have depressed shares prices because they have been sold over the past several months.

    Invest a few minutes of your time to read the 10Q for yourself and confirm an exceptional opportunity.

    MHCC is a very strong buy!

    Sentiment: Strong Buy

  • Millennium Healthcare (MHCC) just reported $6.3 million, a 1,200% increase in revenues in its recent 10Q filing.

    Because Millennium’s diagnostics are preventive, FDA approved, reimbursable and cost patients little to nothing, and because they add significant income for physicians, sales are beginning to increase exponentially.

    Millennium’s gross margins are exceptionally high as the equipment and associated costs typically pays for themselves in the first 30 days of installation.

    Millennium’s network is projected to grow dramatically and sales and earnings are in the early part of a steep growth curve.

    $6.3 million was achieved with only a small number of Millennium’s the current 1,300 physician offices.

    There are over 30,000 primary care offices.

    Millennium has the potential to sign a large number of the 30,000 plus offices.

    At 40 cents Millennium shares are a ground floor opportunity.

    Shares are exceptionally cheap because the company has paid many bills with shares of stock that have depressed shares prices because they have been sold over the past several months.

    Invest a few minutes of your time to read the 10Q for yourself and confirm an exceptional opportunity.

    Sentiment: Strong Buy

  • Reply to

    BioLargo Is On the Oil Industry’s Radar Again

    by stocks4show Nov 13, 2014 3:16 PM
    faststocks7 faststocks7 Nov 18, 2014 4:04 PM Flag

    BLGO also on investors and traders radar.

    Sentiment: Strong Buy

  • "New Technology", a trade magazine for the giant "Oil Patch" industry has just awarded BioLargo (BLGO) AOS Filter technology with their coveted “New Technology” award.

    The word about the breakthrough AOS Filter technology has been leaking out since early this year, but now with a recognized industry publication featuring BioLargo’s AOS Filter, the big oil companies are likely to be accelerating talks with BioLargo for licensing deals and strategic partnerships/investments.

    The AOS Filter has been validated by the University of Alberta to decontaminate water in seconds versus the hours required by current technology . . . and to require only 1/20th of the operating cost of the closest competing technology.

    This is by far the biggest breakthrough in water decontamination/filtration in decades and is expected to have an enormous impact on every sector of the water treatment industry.

    The University is working with BioLargo and a consortium of large oil companies that are active in Canadian oil sands production to commercialize the AOS Filter in an actual field recovery operation. BioLargo is the Chair of this joint effort.

    Since the AOS Filter is so efficient and so inexpensive to operate and since it is effective against so many pathogens and toxic pollutants, its value is likely to be extraordinary. The water treatment industry is estimated to be over $350 billion today and projected to be in the trillions by 2020.

    BioLargo (BLGO) has been trading between $.40 and $1.24 since April.

    Sentiment: Strong Buy

  • "New Technology", a trade magazine for the giant "Oil Patch" industry has just awarded BioLargo (BLGO) AOS Filter technology with their coveted “New Technology” award.

    The word about the breakthrough AOS Filter technology has been leaking out since early this year, but now with a recognized industry publication featuring BioLargo’s AOS Filter, the big oil companies are likely to be accelerating talks with BioLargo for licensing deals and strategic partnerships/investments.

    The AOS Filter has been validated by the University of Alberta to decontaminate water in seconds versus the hours required by current technology . . . and to require only 1/20th of the operating cost of the closest competing technology.

    This is by far the biggest breakthrough in water decontamination/filtration in decades and is expected to have an enormous impact on every sector of the water treatment industry.

    The University is working with BioLargo and a consortium of large oil companies that are active in Canadian oil sands production to commercialize the AOS Filter in an actual field recovery operation. BioLargo is the Chair of this joint effort.

    Since the AOS Filter is so efficient and so inexpensive to operate and since it is effective against so many pathogens and toxic pollutants, its value is likely to be extraordinary. The water treatment industry is estimated to be over $350 billion today and projected to be in the trillions by 2020.

    BioLargo (BLGO) has been trading between $.40 and $1.24 since April.

    Sentiment: Strong Buy

  • "New Technology", a trade magazine for the giant "Oil Patch" industry has just awarded BioLargo (BLGO) AOS Filter technology with their coveted “New Technology” award.

    The word about the breakthrough AOS Filter technology has been leaking out since early this year, but now with a recognized industry publication featuring BioLargo’s AOS Filter, the big oil companies are likely to be accelerating talks with BioLargo for licensing deals and strategic partnerships/investments.

    The AOS Filter has been validated by the University of Alberta to decontaminate water in seconds versus the hours required by current technology . . . and to require only 1/20th of the operating cost of the closest competing technology.

    This is by far the biggest breakthrough in water decontamination/filtration in decades and is expected to have an enormous impact on every sector of the water treatment industry.

    The University is working with BioLargo and a consortium of large oil companies that are active in Canadian oil sands production to commercialize the AOS Filter in an actual field recovery operation. BioLargo is the Chair of this joint effort.

    Since the AOS Filter is so efficient and so inexpensive to operate and since it is effective against so many pathogens and toxic pollutants, its value is likely to be extraordinary. The water treatment industry is estimated to be over $350 billion today and projected to be in the trillions by 2020.

    BioLargo (BLGO) has been trading between $.40 and $1.24 since April.

    Sentiment: Strong Buy

  • "New Technology", a trade magazine for the giant "Oil Patch" industry has just awarded BioLargo (BLGO) AOS Filter technology with their coveted “New Technology” award.

    The word about the breakthrough AOS Filter technology has been leaking out since early this year, but now with a recognized industry publication featuring BioLargo’s AOS Filter, the big oil companies are likely to be accelerating talks with BioLargo for licensing deals and strategic partnerships/investments.

    The AOS Filter has been validated by the University of Alberta to decontaminate water in seconds versus the hours required by current technology . . . and to require only 1/20th of the operating cost of the closest competing technology.

    This is by far the biggest breakthrough in water decontamination/filtration in decades and is expected to have an enormous impact on every sector of the water treatment industry.

    The University is working with BioLargo and a consortium of large oil companies that are active in Canadian oil sands production to commercialize the AOS Filter in an actual field recovery operation. BioLargo is the Chair of this joint effort.

    Since the AOS Filter is so efficient and so inexpensive to operate and since it is effective against so many pathogens and toxic pollutants, its value is likely to be extraordinary. The water treatment industry is estimated to be over $350 billion today and projected to be in the trillions by 2020.

    BioLargo (BLGO) has been trading between $.40 and $1.24 since April.

    Sentiment: Strong Buy

  • "New Technology", a trade magazine for the giant "Oil Patch" industry has just awarded BioLargo (BLGO) AOS Filter technology with their coveted “New Technology” award.

    The word about the breakthrough AOS Filter technology has been leaking out since early this year, but now with a recognized industry publication featuring BioLargo’s AOS Filter, the big oil companies are likely to be accelerating talks with BioLargo for licensing deals and strategic partnerships/investments.

    The AOS Filter has been validated by the University of Alberta to decontaminate water in seconds versus the hours required by current technology . . . and to require only 1/20th of the operating cost of the closest competing technology.

    This is by far the biggest breakthrough in water decontamination/filtration in decades and is expected to have an enormous impact on every sector of the water treatment industry.

    The University is working with BioLargo and a consortium of large oil companies that are active in Canadian oil sands production to commercialize the AOS Filter in an actual field recovery operation. BioLargo is the Chair of this joint effort.

    Since the AOS Filter is so efficient and so inexpensive to operate and since it is effective against so many pathogens and toxic pollutants, its value is likely to be extraordinary. The water treatment industry is estimated to be over $350 billion today and projected to be in the trillions by 2020.

    BioLargo (BLGO) has been trading between $.40 and $1.24 since April.

    Sentiment: Strong Buy

  • "New Technology", a trade magazine for the giant "Oil Patch" industry has just awarded BioLargo (BLGO) AOS Filter technology with their coveted “New Technology” award.

    The word about the breakthrough AOS Filter technology has been leaking out since early this year, but now with a recognized industry publication featuring BioLargo’s AOS Filter, the big oil companies are likely to be accelerating talks with BioLargo for licensing deals and strategic partnerships/investments.

    The AOS Filter has been validated by the University of Alberta to decontaminate water in seconds versus the hours required by current technology . . . and to require only 1/20th of the operating cost of the closest competing technology.

    This is by far the biggest breakthrough in water decontamination/filtration in decades and is expected to have an enormous impact on every sector of the water treatment industry.

    The University is working with BioLargo and a consortium of large oil companies that are active in Canadian oil sands production to commercialize the AOS Filter in an actual field recovery operation. BioLargo is the Chair of this joint effort.

    Since the AOS Filter is so efficient and so inexpensive to operate and since it is effective against so many pathogens and toxic pollutants, its value is likely to be extraordinary. The water treatment industry is estimated to be over $350 billion today and projected to be in the trillions by 2020.

    BioLargo (BLGO) has been trading between $.40 and $1.24 since April.

    Sentiment: Strong Buy

  • Quarter Revenues Increase 12X Setting The Stage For Explosive Growth

    All healthcare companies are not equal.

    Millennium Healthcare (MHCC) just reported a revenue increase to $6 million for the last quarter versus $500,000 a year ago.

    Their new diagnostics are working and selling beyond expectations as the company continues to attract new physician offices.

    Revenues are projected to continue growing to several hundred million per year on an exponential northeast curve.

    Story is beginning to spread - Formal earnings expected in two weeks - buying is starting and accelerating.

    This growth story will be hot in the coming days weeks months and years.

    Sentiment: Strong Buy

AXGN.OB
3.850.0000(0.00%)Feb 24 10:38 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.